Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Whether providing seed funding to startups, growth capital to early-stage companies, or financing buyouts, venture capital funding plays a critical role in sustaining the life sciences ecosystem.
Our global team of venture capital lawyers advise venture capital funds, life sciences companies with a captive venture fund, as well as universities and other academic research institutions. We provide multidisciplinary advice throughout the "venture capital lifecycle from company formation through fundraising and investments to eventual exit.
Regulation is simply a reality of doing business in this industry. Our venture capital lawyers regularly access our world-renowned global regulatory team to perform due diligence investigations of regulatory issues and risk factors, including the relevant approval pathway and reimbursement strategy for your product. We also serve as special regulatory counsel to issuers and underwriters in conjunction with initial public offerings and follow-on offerings.
Many of our team members have in-depth experience in industry and government, including at the FDA and other key regulatory agencies, and hold advance degrees in relevant disciplines.
Key contacts
Representative experience
6
6
Avelios Medical, a Germany-based software company digitalizing hospital workflows and data-driven patient care, on its €30m Series A funding round led by Sequoia Capital.
Sartorius on various venture capital investments in the United Kingdom, the United States, and Germany.
Berlin-based FemTech scale-up Clue (BioWink GmbH) on a strategic investment by Verdane.
Novartis Institutes for Biomedical Research on a number of venture capital transactions.
OncoVerity, a pioneer in applying advanced bioinformatics to drug development, on the closing of a Series A extension financing led by existing investors, argenx and RefinedScience.
Rice University on its launch of RBL LLC, a biotech venture creation studio developed out of the Rice Biotech Launch Pad, the university’s biotech innovation accelerator.
Resources
.jpg?h=399&iar=0&w=1366&hash=1276381413D409DBD36F2372BE264A40)
You may also be interested in...
In-person event
ABA’s Antitrust in Healthcare Conference
20 May 2026 | 8:00 a.m. - 6:00 p.m. (EST)
United States
Sponsorships and Speaking Engagements
Biotech Showcase and exclusive reception during the J.P. Morgan 41st Annual Healthcare Conference
9-12 January 2023
Hogan Lovells Events
Dinner, drinks, and discussion on the impacts of the Inflation Reduction Act of 2022
01 December 2022 | 05:30 PM - Registration and cocktails | 06:30 PM - Dinner and discussion (EST)
Press releases
Hogan Lovells advises MedKitDoc on seed financing in the amount of EUR 7 million
18 January 2022
Press releases
Hogan Lovells advises Engrail Therapeutics on Series A financing extension to US$64 million
04 August 2021
In-person event
ABA’s Antitrust in Healthcare Conference
20 May 2026 | 8:00 a.m. - 6:00 p.m. (EST)
United States
Sponsorships and Speaking Engagements
Biotech Showcase and exclusive reception during the J.P. Morgan 41st Annual Healthcare Conference
9-12 January 2023
Hogan Lovells Events
Dinner, drinks, and discussion on the impacts of the Inflation Reduction Act of 2022
01 December 2022 | 05:30 PM - Registration and cocktails | 06:30 PM - Dinner and discussion (EST)
Press releases
Hogan Lovells advises MedKitDoc on seed financing in the amount of EUR 7 million
18 January 2022
Press releases
Hogan Lovells advises Engrail Therapeutics on Series A financing extension to US$64 million
04 August 2021
